Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04480853 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04480853 · ClinicalTrials.gov record · last posted 2026-06-26

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Name: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis — clinical trial record (NCT04480853)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SPRING

StatusRecruiting

PhasePhase 4

SponsorNovartis Pharmaceuticals

Started2020-10-12

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.

Amendment record 17 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 17 times since 2020-07-17; most recent amendment 2026-06-25. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2020-11-03

Status change Not Yet Recruiting→Recruitingv3

Trial Details

NCT Number	NCT04480853
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Multiple Sclerosis
Enrollment	30 participants
Start Date	2020-10-12
Primary Completion	2027-09-30 (estimated)
Study Completion	2027-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-26